Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)	6 Months Ended		102 Months Ended
	Jun. 30, 2012	Jun. 30, 2011	Jun. 30, 2012 Since Inception
Cash Flows From Operating Activities
Net loss	$ (4,469,483)	$ (3,451,946)	$ (92,560,498)
Adjustments to reconcile net loss to net cash used in operating activities:
Gain on sale of discontinued operation	0	0	(6,408,603)
Gain on sale of warrants	0	0	(518,622)
Loss on abandonment of leaseholds	0	0	135,344
Depreciation	48,575	52,582	2,051,880
Amortization-intangibles	0	0	2,696,193
Amortization-debt discount	0	0	5,291,019
Amortization-deferred financing costs	0	0	925,859
Amortization-technology and product license fee	67,204	45,454	169,477
Provision for obsolete inventory	0	0	200,000
Change in fair value of warrants	(64,157)	(300,571)	(10,395,709)
Common stock and warrants issued for services and reimbursement of expenses	0	0	203,882
Stock based compensation expense	86,845	81,529	7,514,920
In-Process Purchased Technology	0	0	2,027,529
Changes in operating assets and liabilities
Accounts receivable	(9,757)	0	69,231
Inventories	(337,737)	0	(2,578,026)
Prepaid expenses and other assets	(113,956)	(12,339)	(294,750)
Deposits	0	0	(189,750)
Accounts payable	(110,603)	34,198	1,775,705
Accrued liabilities	(46,448)	11,866	(264,672)
Deferred rent	(31,287)	(20,550)	87,026
Net cash used in operating activities	(4,980,804)	(3,559,777)	(90,062,565)
Cash Flows From Investing Activities
In-process technology purchased from Tissue Repair Company	0	0	(1,500,000)
Fee paid to list shares issued for technology and product license	0	0	(65,000)
Purchases of property and equipment	(15,866)	(1,358)	(2,832,417)
Net cash used in investing activities	(15,866)	(1,358)	(4,397,417)
Cash Flows From Financing Activities
Proceeds from officer loan	0	0	62,882
Cash acquired in acquisitions	0	0	1,551,800
Restricted cash - collateral for letter of credit	150,000	100,000	(50,000)
Restricted cash - proceeds placed in escrow from sale of business	0	0	0
Proceeds from the exercise of warrants, net	0	0	1,258,448
Proceeds from debt financing agreement, net of debt issuance costs of $871,833	0	0	14,378,167
Proceeds from the sale of business unit	0	0	11,250,000
Repayment of debt	0	0	(15,750,000)
Proceeds from sales of common stock, net of issuance cost	6,396,891	0	88,030,185
Net cash provided by financing activities	6,546,891	100,000	100,731,482
Net increase (decrease) in cash	1,550,221	(3,461,135)	6,271,500
Cash and cash equivalents at beginning of period	4,721,279	6,644,054	0
Cash and cash equivalents at end of period	6,271,500	3,182,919	6,271,500
Supplemental Disclosures of Cash Flow Information:
Cash paid for interest	2,114	2,170	1,390,915
Cash paid for income taxes	2,400	2,400	28,562
Non-Cash Activity:
Subscription receivable for common shares	0	0	17,000
Common Stock Issued for Repayment of Loans	0	0	62,882
Stock issued for technology license fee	0	0	1,000,000
Net assets acquired for the issuance of common stock (exclusive of cash acquired)	0	0	5,824,000
Warrants exchanged for stock	0	0	(901,139)
Reclassification of derivative liabilities with expired price protection provisions	(21,349)	0	(4,045,702)
Issuance of note for accrued milestone payment	$ 0	$ 0	$ 500,000